Involvement of NMDA receptor complex in the anxiolytic-like effects of chlordiazepoxide in mice

Journal of Neural Transmission

Volumn 118, Issue 6, 2011, Pages 857-864

  Poleszak, Ewa ^a   Socała, Katarzyna ^b   Szopa, Aleksandra ^a   Wróbel, Andrzej ^a   Szewczyk, Bernadeta ^c   Kasperek, Regina ^a   Blicharska, Eliza ^a   Nowak, Gabriel ^c,d   Wlaź, Piotr ^b  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

^b MARIA CURIE SK ODOWSKA UNIVERSITY   (Poland)

^c INSTITUTE OF PHARMACOLOGY   (Poland)

^d JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Anxiety; Chlordiazepoxide; Elevated plus maze; Mice; NMDA receptor ligands

Indexed keywords

2 AMINO 4 METHYL 5 PHOSPHONO 3 PENTENOIC ACID; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 7 CHLORO 4 HYDROXY 3 (3 PHENOXYPHENYL) 2 QUINOLONE; BENZODIAZEPINE; CHLORDIAZEPOXIDE; CYCLOSERINE; DEXTRO SERINE; GLUTAMIC ACID; GLYCINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; MALE; MAZE TEST; MOUSE; NEUROTRANSMISSION; NONHUMAN; PRIORITY JOURNAL; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; CHLORDIAZEPOXIDE; GABA MODULATORS; GAMMA-AMINOBUTYRIC ACID; GLUTAMIC ACID; MALE; MICE; RECEPTORS, N-METHYL-D-ASPARTATE;

EID: 80051669613     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-011-0585-x     Document Type: Article

References (51)

1. Aboujaoude E, Barry JJ, Gamel N (2009) Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an openlabel trial. J Clin Psychopharmacol 29:51-55
2. Abramowitz JS, Taylor S, McKay D (2009) Obsessive-compulsive disorder. Lancet 374:491-499
3. Amiel JM, Mathew SJ (2007) Glutamate and anxiety disorders. Curr Psychiatry Rep 9:278-283 (Pubitemid 47489998)
4. Anthony EW, Nevins ME (1993) Anxiolytic-like effects of N-methyl-D-aspartate-associated glycine receptor ligands in the rat potentiated startle test. Eur J Pharmacol 250:317-324 (Pubitemid 23357382)
5. Boyce-Rustay JM, Holmes A (2006) Genetic inactivation of the NMDA receptor NR2A subunit has anxiolytic-and antidepressant-like effects in mice. Neuropsychopharmacology 31:2405-2414 (Pubitemid 44607058)
6. Campeau S, Miserendino MJ, Davis M (1992) Intra-amygdala infusion of the N-methyl-D-aspartate receptor antagonist AP5 blocks acquisition but not expression of fear-potentiated startle to an auditory conditioned stimulus. Behav Neurosci 106:569-574
7. Coric V, Taskiran S, Pittenger C, Wasylink S, Mathalon DH, Valentine G, Saksa J, Wu YT, Gueorguieva R, Sanacora G, Malison RT, Krystal JH (2005) Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol Psychiatry 58:424-428 (Pubitemid 41219711)
8. Dunn RW, Corbett R, Fielding S (1989) Effects of 5-HT1A receptor agonists and NMDA receptor antagonists in the social interaction test and the elevated plus maze. Eur J Pharmacol 169:1-10 (Pubitemid 19244943)
9. Emmett MR, Mick SJ, Cler JA, Rao TS, Iyengar S, Wood PL (1991) Actions of D-cycloserine at the N-methyl-D-aspartate-associated glycine receptor site in vivo. Neuropharmacology 30:1167-1171
10. Fendt M, Koch M, Schnitzler HU (1996) NMDA receptors in the pontine brainstem are necessary for fear potentiation of the startle response. Eur J Pharmacol 318:1-6 (Pubitemid 27033195)
11. Feusner JD, Kerwin L, Saxena S, Bystritsky A (2009) Differential efficacy of memantine for obsessive-compulsive disorder vs. generalized anxiety disorder: an open-label trial. Psychopharmacol Bull 42:81-93
12. Heresco-Levy U, Kremer I, Javitt DC, Goichman R, Reshef A, Blanaru M, Cohen T (2002) Pilot-controlled trial of D-cycloserine for the treatment of post-traumatic stress disorder. Int J Neuropsychopharmacol 5:301-307 (Pubitemid 35470350)
13. Ho YJ, Hsu LS, Wang CF, Hsu WY, Lai TJ, Hsu CC, Tsai YF (2005) Behavioral effects of D-cycloserine in rats: the role of anxiety level. Brain Res 1043:179-185
14. Hood WF, Compton RP, Monahan JB (1989) D-cycloserine: a ligand for the N-methyl-D-aspartate coupled glycine receptor has partial agonist characteristics. Neurosci Lett 98:91-95 (Pubitemid 19054324)
15. Johnson JW, Ascher P (1987) Glycine potentiates the NMDA response in cultured mouse brain neurons. Nature 325:529-531 (Pubitemid 17056733)
16. Kalueff A, Nutt DJ (1996) Role of GABA in memory and anxiety. Depress Anxiety 4:100-110 (Pubitemid 27237372)
17. Karcz-Kubicha M, Jessa M, Nazar M, Plaźnik A, Hartmann S, Parsons CG, Danysz W (1997) Anxiolytic activity of glycine-B antagonists and partial agonists-no relation to intrinsic activity in the patch clamp. Neuropharmacology 36:1355-1367 (Pubitemid 27502193)
18. Kessler M, Terramani T, Lynch G, Baudry M (1989) A glycine site associated with N-methyl-D-aspartic acid receptors: characterization and identification of a new class of antagonists. J Neurochem 52:1319-1328 (Pubitemid 19085960)
19. Kew JN, Kemp JA (2005) Ionotropic and metabotropic glutamate receptor structure and pharmacology. Psychopharmacology (Berl) 179:4-29 (Pubitemid 40576690)
20. Kleckner NW, Dingledine R (1988) Requirement for glycine in activation of NMDA-receptors expressed in Xenopus oocytes. Science 241:835-837
21. Kleckner NW, Dingledine R (1989) Selectivity of quinoxalines and kynurenines as antagonists of the glycine site on N-methyl-D-aspartate receptors. Mol Pharmacol 36:430-436 (Pubitemid 19245389)
22. Kłodzińska A, Chojnacka-Wójcik E (2000) Anticonflict effect of the glycineB receptor partial agonist, D-cycloserine, in rats. Pharmacological analysis. Psychopharmacology (Berl) 152:224-228
23. Kotlińska J, Liljequist S (1998) A characterization of anxiolytic-like actions induced by the novel NMDA/glycine site antagonist, L-701, 324. Psychopharmacology (Berl) 135:175-181 (Pubitemid 28055501)
24. Krystal JH, D'Souza DC, Petrakis IL, Belger A, Berman RM, Charney DS, Abi-Saab W, Madonick S (1999) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv Rev Psychiatry 7:125-143 (Pubitemid 30240826)
25. Lipman JJ, Spencer PS (1980) Rapid intracerebroventricular injection assisted by an automatic syringe. J Pharmacol Methods 4:327-333 (Pubitemid 11125776)
26. Lister RG (1987) The use of a plus-maze to measure anxiety in the mouse. Psychopharmacology (Berl) 92:180-185 (Pubitemid 17072893)
27. Lydiard RB (2003) The role of GABA in anxiety disorders. J Clin Psychiatry 64(Suppl 3):21-27 (Pubitemid 36389868)
28. Mathew SJ, Amiel JM, Coplan JD, Fitterling HA, Sackeim HA, Gorman JM (2005) Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379-2381 (Pubitemid 41740219)
29. Nemeroff CB (2003) The role of GABA in the pathophysiology and treatment of anxiety disorders. Psychopharmacol Bull 37:133-146
30. A-benzodiazepine receptor in psychiatric disorder. Br J Psychiatry 179:390-396 (Pubitemid 33097160)
31. Parsons CG, Danysz W, Quack G (1998) Glutamate in CNS disorders as a target for drug development: an update. Drug News Perspect 11:523-569 (Pubitemid 29086561)
32. Pellow S (1986) Anxiolytic and anxiogenic drug effects in a novel test of anxiety: are exploratory models of anxiety in rodents valid? Methods Find Exp Clin Pharmacol 8:557-565 (Pubitemid 17208023)
33. Pellow S, Chopin P, File SE, Briley M (1985) Validation of open:closed arm entries in an elevated plus-maze as a measure of anxiety in the rat. J Neurosci Methods 14:149-167 (Pubitemid 16239568)
34. Płaźnik A, Pałejko W, Nazar M, Jessa M (1994) Effects of antagonists at the NMDA receptor complex in two models of anxiety. Eur Neuropsychopharmacol 4:503-512
35. Poleszak E, Szewczyk B, Kȩdzierska E, Wlaź P, Pilc A, Nowak G (2004) Antidepressant-and anxiolytic-like activity of magnesium in mice. Pharmacol Biochem Behav 78:7-12 (Pubitemid 38670508)
36. Poleszak E, Wlaź P, Wróbel A, Fidecka S, Nowak G (2008) NMDA/glutamate mechanism of magnesium-induced anxiolytic-like behavior in mice. Pharmacol Rep 60:655-663
37. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (1998) Anxiolytic-and antidepressant-like effects of an antagonist at glycineB receptors. Pol J Pharmacol 50:349-354
38. Przegaliński E, Tatarczyńska E, Chojnacka-Wójcik E (2000) The influence of the benzodiazepine receptor antagonist flumazenil on the anxiolytic-like effects of CGP 37849 and ACPC in rats. Neuropharmacology 39:1858-1864 (Pubitemid 30398489)
39. Ressler KJ, Rothbaum BO, Tannenbaum L, Anderson P, Graap K, Zimand E, Hodges L, Davis M (2004) Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136-1144 (Pubitemid 39463415)
40. Sharma AC, Kulkarni SK (1993) Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behaviour in rats. Indian J Exp Biol 31:191-193 (Pubitemid 23044046)
41. A receptor subtypes. Pharmacol Rev 47:181-234
42. A receptors. Neurochem Int 34:379-385 (Pubitemid 29240634)
43. Stahl SM (2002) Don't ask, don't tell, but benzodiazepines are still the leading treatments for anxiety disorder. J Clin Psychiatry 63:756-757
44. Tricklebank MD, Singh L, Oles RJ, Preston C, Iversen SD (1989) The behavioural effects of MK-801: a comparison with antagonists acting non-competitively and competitively at the NMDA receptor. Eur J Pharmacol 167:127-135 (Pubitemid 19213713)
45. Trullas R, Jackson B, Skolnick P (1989) Anxiolytic properties of 1-aminocyclopropanecarboxylic acid, a ligand at strychnineinsensitive glycine receptors. Pharmacol Biochem Behav 34:313-316 (Pubitemid 20009325)
46. Trullas R, Folio T, Young A, Miller R, Boje K, Skolnick P (1991) 1-Aminocyclopropanecarboxylates exhibit antidepressant and anxiolytic actions in animal models. Eur J Pharmacol 203:379-385
47. Uhlenhuth EH, Balter MB, Ban TA, Yang K (1999) International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: IV. Therapeutic dose dependence and abuse liability of benzodiazepines in the longterm treatment of anxiety disorders. J Clin Psychopharmacol 19:23S-29S
48. Watson GB, Bolanowski MA, Baganoff MP, Deppeler CL, Lanthorn TH (1990) D-cycloserine acts as a partial agonist at the glycine modulatory site of the NMDA receptor expressed in Xenopus oocytes. Brain Res 510:158-160 (Pubitemid 20060820)
49. Willetts J, Balster RL, Leander JD (1990) The behavioral pharmacology of NMDA receptor antagonists. Trends Pharmacol Sci 11:423-428 (Pubitemid 20344028)
50. Wood PL, Emmett MR, Rao TS, Mick S, Cler J, Iyengar S (1989) In vivo modulation of the N-methyl-D-aspartate receptor complex by D-serine: potentiation of ongoing neuronal activity as evidenced by increased cerebellar cyclic GMP. J Neurochem 53:979-981 (Pubitemid 19207403)
51. Wood PL, Hawkinson JE, Goodnough DB (1996) Formation of D-serine from L-phosphoserine in brain synaptosomes. J Neurochem 67:1485-1490 (Pubitemid 26314204)